Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Novonesis

434.20 DKK-0.55 %7/9 9:31
Less than 1K followers

NSIS B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-0.55 %
+2.19 %
+18.28 %
+19.45 %
+6.47 %
+5.98 %
+41.76 %
-12.83 %
+1,073.51 %

Novonesis is a biochemistry company. The company develops enzymes and various microorganisms for industrial use. The enzymes are a protein used in a number of different industries, mainly in the agricultural and food industries. Novonesis products are used in various foods and clothing and the company holds sales on a global level. Novonesis was founded in 1921 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
203.34B DKK
Turnover
12.29M DKK
Revenue
31.05B
EBIT %
19.64 %
P/E
46.51
Dividend yield-%
0.98 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
11/2
2027

Annual report '26

All
Research
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release2026-09-02 09:38

Novonesis to build next generation enzyme production facility in India

Novonesis
Regulatory press release2026-08-25 09:12

Trading by management and close relations of management

Novonesis
Press release2026-08-19 18:25

H1 2026: Novonesis delivered strong 8% organic sales growth and increases full-year outlook

Novonesis

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Analyst Comment2026-08-19 18:24

HCA Red Flag: Novonesis raises guidance and initiates a 1 BEUR share buyback (AI)

Expect a positive opening. Novonesis raised its full-year growth guidance to 7-8% vs. the 6.9% analysts expected and announced its first share buyback of 1 BEUR. EUR. The counterweight is the largest division, Agriculture, Energy & Tech, which grew by 7% vs. the expected 8.6%.

Novonesis
Regulatory press release2026-08-19 17:41

Interim report H1 2026

Novonesis
Regulatory press release2026-08-19 17:41

Announcement of share buyback program

Novonesis
Regulatory press release2026-08-19 17:39

Increased outlook for 2026

Novonesis
Press release2026-08-10 09:24

Novonesis to acquire remaining share of MicroBioGen to strengthen yeast capabilities

Novonesis
Regulatory press release2026-05-06 14:44

Trading by management and close relations of management

Novonesis
Regulatory press release2026-05-05 07:58

Interim report Q1 2026

Novonesis
Regulatory press release2026-03-26 14:44

Trading by management and close relations of management

Novonesis
Regulatory press release2026-03-23 17:54

Resolutions from the Annual General Meeting 2026

Novonesis
Regulatory press release2026-03-23 13:52

Trading by management and close relations of management

Novonesis
Press release2026-03-16 13:14

Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility

Novonesis
Press release2026-03-13 09:56

Novonesis issues EUR 1.7 billion senior unsecured notes

Novonesis
Regulatory press release2026-03-11 13:38

Trading by management and close relations of management

Novonesis
Regulatory press release2026-02-27 10:22

Trading by management and close relations of management

Novonesis
Regulatory press release2026-02-26 17:04

Trading by management and close relations of management

Novonesis
Regulatory press release2026-02-26 12:00

Invitation to the 2026 Annual General Meeting

Novonesis
Regulatory press release2026-02-26 11:23

Trading by management and close relations of management

Novonesis